Leerink Partnrs Has Positive Outlook for IONS Q2 Earnings

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Equities research analysts at Leerink Partnrs lifted their Q2 2025 earnings estimates for Ionis Pharmaceuticals in a research note issued on Thursday, July 17th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will earn $0.31 per share for the quarter, up from their previous forecast of ($0.93). The consensus estimate for Ionis Pharmaceuticals' current full-year earnings is ($3.50) per share. Leerink Partnrs also issued estimates for Ionis Pharmaceuticals' Q3 2025 earnings at ($1.17) EPS, Q4 2025 earnings at ($1.19) EPS, FY2025 earnings at ($3.00) EPS, FY2026 earnings at ($3.52) EPS, FY2027 earnings at ($1.87) EPS, FY2028 earnings at ($1.61) EPS and FY2029 earnings at $1.31 EPS.

IONS has been the topic of a number of other research reports. Needham & Company LLC decreased their price target on shares of Ionis Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. Guggenheim lowered their price target on shares of Ionis Pharmaceuticals from $65.00 to $64.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. Redburn Atlantic initiated coverage on shares of Ionis Pharmaceuticals in a research report on Monday, March 31st. They set a "neutral" rating and a $39.00 price target on the stock. Barclays raised shares of Ionis Pharmaceuticals from an "equal weight" rating to an "overweight" rating and raised their price target for the stock from $51.00 to $57.00 in a research report on Tuesday, July 1st. Finally, JPMorgan Chase & Co. raised their price target on shares of Ionis Pharmaceuticals from $45.00 to $48.00 and gave the stock a "neutral" rating in a research report on Thursday, June 12th. Two research analysts have rated the stock with a sell rating, three have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $57.13.

Ionis Pharmaceuticals Stock Down 1.0%

Shares of IONS opened at $41.76 on Monday. Ionis Pharmaceuticals has a 52 week low of $23.95 and a 52 week high of $52.34. The firm has a market cap of $6.65 billion, a P/E ratio of -13.97 and a beta of 0.23. The firm's 50-day simple moving average is $37.30 and its 200 day simple moving average is $33.55. The company has a debt-to-equity ratio of 2.63, a quick ratio of 9.62 and a current ratio of 9.66.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The company reported ($0.93) EPS for the quarter, beating analysts' consensus estimates of ($1.07) by $0.14. Ionis Pharmaceuticals had a negative net margin of 63.65% and a negative return on equity of 91.85%. The business had revenue of $132.00 million for the quarter, compared to analyst estimates of $144.31 million. During the same quarter in the prior year, the business earned ($0.98) EPS. Ionis Pharmaceuticals's quarterly revenue was up 10.9% on a year-over-year basis.

Institutional Investors Weigh In On Ionis Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Signaturefd LLC boosted its stake in shares of Ionis Pharmaceuticals by 160.0% in the 4th quarter. Signaturefd LLC now owns 949 shares of the company's stock valued at $33,000 after purchasing an additional 584 shares in the last quarter. Huntington National Bank boosted its stake in shares of Ionis Pharmaceuticals by 193.5% in the 4th quarter. Huntington National Bank now owns 951 shares of the company's stock valued at $33,000 after purchasing an additional 627 shares in the last quarter. Raiffeisen Bank International AG acquired a new stake in shares of Ionis Pharmaceuticals in the 4th quarter valued at approximately $62,000. Parallel Advisors LLC boosted its position in Ionis Pharmaceuticals by 151.3% during the 2nd quarter. Parallel Advisors LLC now owns 1,872 shares of the company's stock worth $74,000 after buying an additional 1,127 shares during the period. Finally, Ancora Advisors LLC acquired a new stake in Ionis Pharmaceuticals during the 1st quarter worth approximately $60,000. 93.86% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Michael R. Hayden purchased 15,000 shares of Ionis Pharmaceuticals stock in a transaction dated Thursday, May 1st. The shares were bought at an average cost of $31.86 per share, for a total transaction of $477,900.00. Following the purchase, the director owned 50,219 shares in the company, valued at approximately $1,599,977.34. This trade represents a 42.59% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Brett P. Monia sold 1,160 shares of the firm's stock in a transaction that occurred on Friday, July 11th. The shares were sold at an average price of $41.74, for a total transaction of $48,418.40. Following the completion of the sale, the chief executive officer owned 179,820 shares in the company, valued at approximately $7,505,686.80. The trade was a 0.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.60% of the stock is owned by company insiders.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.